Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13439969 | 0.88 | KMT2A (0.57) | TDP1PKMMAPTMAPK1POLB | |
| SCHEMBL7734041 | 0.88 | TDP1 (0.58) | TDP1PKMMAPTMAPK1ALDH1A1 | |
| SCHEMBL8490992 | 0.86 | TDP1 (0.70) | TDP1PKMMAPTMAPK1POLB | |
| SCHEMBL17881359 | 0.85 | TDP1 (0.54) | TDP1PKMMAPK1ALDH1A1KMT2A | |
| SCHEMBL14035607 | 0.85 | TDP1 (0.54) | TDP1PKMMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12393859 | 0.85 | ADRB2 (0.55) | TDP1PKMMAPK1ALDH1A1ADRB2 | |
| SCHEMBL7225692 | 0.84 | TDP1 (0.63) | TDP1PKMMAPTMAPK1POLB | |
| SCHEMBL9319093 | 0.84 | HTR3A (0.66) | TDP1PKMMAPTMAPK1POLB | |
| SCHEMBL13439967 | 0.83 | TDP1 (0.62) | TDP1PKMMAPTMAPK1POLB | |
| SCHEMBL31555691 | 0.83 | TDP1 (0.62) | TDP1PKMMAPTMAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270859-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-8207179-B2 | Substituted indolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20100222331-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100184747-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-2181108-A2 | 3-HETROCYCLYLIDENE-INDOLINONE DERIVATIVES AS INHIBITORS OF SPECIFIC CELL CYCLE KINASES | Boehringer Ingelheim International GmbH (DE) | 2010-05-05 | — | — | EP | disclosed |
| EP-2167465-A1 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Boehringer Ingelheim International GmbH (DE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008152014-A2 | 3-HETROCYCLYLIDENE-INDOLINONE DERIVATIVES AS INHIBITORS OF SPECIFIC CELL CYCLE KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152013-A1 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270859-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | IDO1, INMT, TPH1 | TDP1 733/4885PKM 900/4885MAPT 1127/4885 |
| US-20100184747-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | IDO1, INMT, TPH1 | TDP1 733/4885PKM 900/4885MAPT 1127/4885 |
| US-20100222331-A1 | NEW COMPOUNDS | CCNA1, CCNY, MKI67 | TDP1 1954/4885PKM 1535/4885MAPT 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.